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Abstract Sleepwalking (SW) corresponds to a complex
sleep-associated behavior that includes locomotion, mental
confusion, and amnesia. SW is present in about 10% of
children and 2–3% of adults. In a retrospective series of
165 patients with Parkinson’s disease (PD), we found
adult-onset (‘‘de novo’’) SW ‘‘de novo’’ in six (4%) of
them. The aim of this study was to assess prospectively and
systematically the frequency and characteristics of SW in
PD patients. A questionnaire including items on sleep
quality, sleep disorders, and specifically also SW and REM
sleep behavior disorder (RBD), PD characteristics and
severity, was sent to the members of the national PD
patients organization in Switzerland. In the study, 36/417
patients (9%) reported SW, of which 22 (5%) had adult-
onset SW. Patients with SW had significantly longer dis-
ease duration (p = 0.035), they reported more often hal-
lucinations (p = 0.004) and nightmares (p = 0.003), and
they had higher scores, suggestive for RBD in a validated
questionnaire (p = 0.001). Patients with SW were also
sleepier (trend to a higher Epworth Sleepiness Scale score,
p = 0.055). Our data suggest that SW in PD patients is (1)
more common than in the general population, and (2) is
associated with RBD, nightmares, and hallucinations.
Further studies including polysomnographic recordings are
needed to confirm the results of this questionnaire-based
analysis, to understand the relationship between SW and
other nighttime wandering behaviors in PD, and to clarify
the underlying mechanisms.
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Introduction
Sleepwalking (SW) corresponds to a complex sleep-asso-
ciated behavior, usually initiated during arousals from
slow-wave sleep, which includes locomotion, mental con-
fusion, and amnesia regarding the episode. Injuries and acts
of violence may also occur [1]. The prevalence of SW in
children is about 10% and in adults is 2–3%. Less than 1%
of adults reported never having walked in sleep in their
childhood (adult-onset SW ‘‘de novo’’) [2]. Most com-
monly, SW appears in the context of a non-rapid eye
movement (NREM) sleep parasomnia. However, SW can
also appear in the context of nocturnal epilepsy, para-
somnia overlap disorder, in which rapid eye movement
(REM) and NREM features are combined, and psychiatric
disorders [3]. SW is thought to arise from a dissociation
between motor and mental arousal, as also suggested by a
study using single-photon emission computed tomography
[4]. Polysomnographic findings indicate an incomplete
awakening that includes residual stage I theta patterns,
some persistent slow-wave activity, and a diffuse and
poorly reactive alpha rhythm [5]. In a patient with confu-
sional arousals, which is an arousal parasomnia associated
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with SW, Terzaghi et al. [6] succeeded in showing disso-
ciated brain activity by intracerebral electroencephalogra-
phy and evidenced these concurrently arising different
states of being (i.e., wakefulness and NREM) as local brain
phenomena.
An association of SW with Parkinson disease (PD) has
been reported in an abstract form in three patients [7]. In
two series of patients with REM sleep behavior disorder
(RBD) and PD, one out of 100 consecutive patients and
two of 66, respectively, had SW [8, 9]. We recently
described SW in six out of 165 consecutive patients in a
retrospective case series [10]. Sleepwalking/nighttime
wandering has also been reported in ten of 93 Caucasian
patients with RBD of different origin, including PD. Five
of these ten patients had an underlying unspecified neuro-
degenerative disorder [11]. Night-wandering was also
recently described in 11 of 70 Asian patients with RBD.
Twenty-four had a symptomatic RBD, 11 of which had PD
[12]. In questionnaire-based studies asking for sleepwalk-
ing/nighttime wandering in PD patients, frequencies rang-
ing from 2% (4/201) [13], 3% (2/61, resp. 2/66) [9, 14] to
5% (16/303) [15] can be found in the literature, however,
no detailed characteristics of the phenomenon were stud-
ied. The aim of the present study was to assess frequency
and characteristics of SW/nighttime wandering in patients
with PD.
Patients and methods
A questionnaire including items on sleep quality, sleep
disorders, and specifically SW and RBD, PD characteris-
tics, and severity, was sent to the members of the national
PD patients organization in Switzerland. Members of the
organization are not only PD patients but also their care-
givers and relatives as well as many physicians. The
questionnaire consists of 17 items on sleep and sleep dis-
orders in general, including sleep duration, sleep-onset
insomnia, sleep latency, sleep-maintenance insomnia,
awakenings at night and their causes, early morning
awakening, snoring, symptoms suggestive of sleep apnea,
sleep talking, verbal and physical violence, restless legs
symptoms, dream recall, variation of dream content, and
nightmares and hallucinations. Possible answers include
‘‘yes’’ and ‘‘no’’ or provide a rating on a five-point scale
depending on the frequency of occurrence (‘‘almost
always’’, ‘‘often’’, ‘‘occasionally’’, ‘‘seldom’’, or ‘‘never’’).
As a screening question for restless legs syndrome (RLS),
the single validated question, suggested from the Interna-
tional RLS Study group was used [16]. All patients were
asked if they had SW in childhood and/or as adults. The
reported presence of SW was the main outcome measure of
the study. The patients with SW filled in a more detailed
questionnaire with 22 items on frequency of SW, occur-
rence during the night, recall, awakening during SW, most
common and most complex activities, relation of SW
behavior to dreams, injuries, violence, family history,
precipitating factors.
Three validated scores were included in the question-
naire: the Epworth Sleepiness Scale (ESS) was used to
assess subjective daytime sleepiness, the Activities of daily
living (ADL) score according to Schwab and England was
used as a marker of disease severity and the REM sleep
behavior disorder screening questionnaire (RBDSQ) to
assess RBD [17]. RBDSQ is a self-assessment tool con-
sisting of ten items. Each question requires a ‘‘yes’’ or
‘‘no’’ answer. A cut-off score of five points was demon-
strated to be suggestive of RBD—with a high sensitivity
(96%) and specificity (92%) in idiopathic cases, but low
specificity (56%) in cases with concomitant sleep disor-
ders, especially in SW.
PD characteristics were addressed by six items gathering
information on first symptoms, first diagnosis, and start of
treatment, invasive treatment, and type of the PD. Fur-
thermore, we asked patients to list their current medication.
All patients also provided information and allowed us to
contact their physicians if confirmation of the diagnosis
was needed. Help from partners/caregivers was encouraged
but was not mandatory. The study was approved by the
local ethics committee and all patients signed an informed
consent form (attached to the questionnaire).
Statistical analysis was performed using SPSS 15 soft-
ware. Patients with SW were compared with patients
without SW. Chi-square, t tests, and Mann–Whitney tests
were used to analyze categorical and continuous variables,
respectively. The significance level was set at p \ 0.05.
Missing cases were excluded analysis by analysis.
Results
A total of 417 questionnaires were returned. Characteristics
of the study population are listed in Table 1. In 255 cases
(61%), help from caregivers for filling in the questionnaire
was reported.
Thirty-six (9%) out of 417 adult PD patients reported
SW. Fourteen patients (3%) had SW since childhood,
and in three of them it persisted throughout their lives.
The remaining 22 patients (5%) had adult-onset SW,
which appeared right before or after the diagnosis of PD
onset.
The characteristics of patients with and without SW are
presented in Table 2. Patients with SW showed a signifi-
cantly longer disease duration (13.1 ± 9.0 vs. 10.3 ± 7.1;
p = 0.035). However, no difference could be found com-
paring the ADL score (72 vs. 76%; p = 0.25).
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Hallucinations (p = 0.001) and nightmares (p = 0.006)
occurred more often in the sleepwalkers’ group. In addi-
tion, they admitted their dream content and intensity to
have changed recently, compared to the non-SW group
(p = 0.031).
Patients with SW had significantly higher scores on the
RBDSQ (6.8 ± 3.3 vs. 5 ± 3; p = 0.001). Twenty-six out
of the 36 SW patients (72%) had scores C5, which is
suggestive of RBD according to the literature [17].
There was a trend for higher ESS scores (p = 0.055) in
patients with SW corresponding to a more pronounced
excessive daytime sleepiness (EDS) (11.8 ± 5.7 vs.
10 ± 5.3).
When asked for the most complex action during SW,
patients listed the following behaviors: preparing eggs for a
meal, passing water in the corner of the room, fishing in the
lake, climbing on furniture, shouting out of the window,
trying to open the door of the apartment, framing pictures,
opening the house door and climbing downstairs, taking
down a painting from the wall, climbing over the bed
railings and pacing around, singing, carrying towels and
clothes out of the room, taking the window out of its frame,
kicking the partner’s legs. Several falls and jumps were
mentioned as well.
The most common activities during SW are presented in
Fig. 1.
Injuries during SW occurred in six (17%) out of 36
patients: bruises and contusions, bruises with wounds,
hematoma on the thigh with residual dents, thumb and
fingers injury, bleeding head injury, femoral neck fracture.
The most frequent factor that was reported to trigger SW
was the full moon (11/36). Other triggers included ‘‘stress’’
(eight), alcohol (seven), pain (two), medications (two, once
biperiden named, once zolpidem and pramipexole), ‘‘oth-
ers’’ (two), and sleep deprivation (one).
No significant differences were found comparing results
of questions asking for or suggesting other sleep disorders
such as initiation and maintenance insomnia, snoring and
sleep apnea, cursing and violence during sleep, restless
legs, and dream recall.
Thirty-two (89%) patients received dopaminergic treat-
ment. Out of these patients, 17 were treated with a combi-
nation of levodopa and a dopamine agonist, ten received a
levodopa monotherapy, and five a dopamine agonist
monotherapy. Other treatments included COMT inhibitors
(n = 8), amantadine (n = 5, 14%), MAO-B inhibitors
(n = 6, 17%), antidepressants (n = 9, 25%) including
selective serotonin reuptake inhibitors (SSRIs, n = 2),
serotonin-norepinephrine reuptake inhibitors (SNRIs,
n = 1), tricyclics (n = 5) 5, mianserin (n = 1), neuroleptics
(n = 4), rivastigmine (n = 2), and benzodiazepines
(n = 3). There were no differences regarding the therapy
(including neurosurgical treatment) between patients with
and without SW except for a trend towards a slightly higher
percentage of patients taking tricyclic antidepressants (14%)
compared to the patients without SW (6%), p = 0.072.
Table 1 Demographic and
clinical characteristics and
treatment of the studied PD
population (n = 417)
ESS Epworth Sleepiness Scale
(score), ADL activities in daily
life score according to Schwab
and England
a Number of patients receiving
help from their caregivers or
bed partners to fill in the
questionnaire
b Thirteen patients did not
provide information on their
therapy. Additionally, 36
patients did not provide the
exact doses of the dopaminergic
drugs
c Including imidazopyridines
Variable Mean ± SD or %, range Missing cases, n
Age (years) 69.4 ± 9.1, 39–99 17
Gender 68% men 2
ESS 10.1 ± 5.3, 0–24 28
ESS C10 47 28
Sleep problem (%) 56.6 21
Disease duration (years) 10.5 ± 7.3, 0.5–54 32
ADL (%) 75.6 ± 16.7, 10–100 9
Help from caregiversa 255 (61%) 14
Therapy b
Levodopa equivalent dose (mg) 686 ± 389, 0–2,869
COMT inhibitors (%) 27
Amantadine (%) 12
Biperiden (%) 5
MAO-B inhibitors (%) 12
Antidepressants (%) 22
Neuroleptics (%) 8
Benzodiazepinesc (%) 14
Dementia medication (%) 3
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Discussion
Thirty-six (9%) out of 417 patients reported adult SW, and
of them, 22 (5% of the population studied) reported adult-
onset (‘‘de novo’’) SW. Patients with SW had significantly
longer disease duration; more hallucinations, nightmares,
recent changes of their dream content; and higher scores in
a validated questionnaire for REM sleep behavior disorder.
Patients with SW also tended to be sleepier and to use
tricyclic antidepressants more often.
Sleepwalking and Parkinson’s disease: prevalence
Compared to the prevalence found in a large Finnish study
[2], SW in patients with PD appears to be more frequent (9
vs. 2–4%). Comparing only adult-onset or ‘‘de novo’’ SW,
we found a frequency considerably higher in the study
population (5%) than in the general population (\1%).
It should, however, be stressed that our data were only
based on information gathered by questionnaire. The dif-
ferentiation of sleepwalking from other nighttime walking
behavior (see below) is therefore not possible. Further
studies including polysomnographic recordings and bed
partner’s reports are needed to elucidate the relationship
between SW and other nighttime wandering behaviors in
PD.
SW appears to be a late manifestation of PD. The longer
disease duration suggests that neurodegenerative changes
in advanced PD enable the clinical manifestation of SW.
On the other hand, it did not correspond to the subjective
grade of disability as expressed by the ADL score. One
possible explanation of our finding could be that severe
motor disability in PD patients prevents them from SW.
Table 2 Characteristics of the patients with and without sleepwalking
Variable Patients with SW, n = 36 Patients without SW, n = 381 p
Mean ± SD, range Missing cases, n Mean ± SD, range Missing cases, n
Age (years) 70.2 ± 8, 55–88 1 69.4 ± 9, 36–99 16 NS
ESS 11.8 ± 5.7, 0–23 3 10 ± 5.3, 0–24 25 0.055
Disease duration (years) 13.1 ± 9, 3–48 3 10.3 ± 7.1, 0.5–54 29 0.035
Disease age (years) 57.1 ± 11.6, 27–78 3 58.9 ± 10.6, 27–88 29 NS
Levodopa equivalent dose (mg) 591 ± 325, 0–1,424 a 695 ± 393, 0–2,869 b NS
ADL 72.4 ± 16.9, 30–90 1 75.8 ± 16.7, 10–100 8 NS
RBD score 6.8 ± 3.3, 1–13 1 5 ± 3, 1–13 12 0.001
Mean sleep duration (h) 6.9 ± 1.7, 3–9.5 0 6.4 ± 1.5, 2–11 20 NS
Sleep onset insomniac 2.5 ± 1.3 2 2.4 ± 1.3 18 NS
Maintenance insomniac 3.3 ± 1.4 2 3.4 ± 1.5 17 NS
Early morning awakeningc 3.2 ± 1.3 0 3 ± 1.3 10 NS
Loud snoringc 2.6 ± 1.4 1 2.6 ± 1.1 23 NS
Apneas/hypopneasc 2.0 ± 1.3 3 1.6 ± 0.9 41 NS
Out of breath at nightc 1.8 ± 0.9 0 1.5 ± 0.8 12 NS
Somniloquyc 2.8 ± 1.1 0 2.4 ± 1.1 11 NS
Cursing/violencec 1.6 ± 0.8 1 1.6 ± 1 17 NS
Restless legs symptomsc 2.4 ± 1.2 1 2.2 ± 1.3 13 NS
Nightmaresc 2.5 ± 1.1 1 2 ± 0.9 10 0.006
Hallucinationsc 2.3 ± 1.3 0 1.7 ± 1 9 0.001
ESS Epworth Sleepiness Scale (score), ADL activities in daily life score according to Schwab and England, RBD (REM sleep behavior disorder)
score according to RBD Screening Questionnaire [17]
a Three patients did not provide information on their therapy and one did not provide the exact doses of the dopaminergic drugs
b Ten patients did not provide information on their therapy and 35 patients did not provide the exact doses of the dopaminergic drugs
c The frequency of the symptom is rated on a five-point scale (1, never; 2, seldom; 3, occasionally; 4, often; 5, almost always) and the p values
represent the significance, based on Mann–Whitney nonparametric test
Number of patients reporting night-time activities
Walk around the
Wake up in front
of a wall
Fall out of bed
house
0 5 10 15 20
Leave the house
Fig. 1 Most common activities during SW
1264 J Neurol (2011) 258:1261–1267
123
However, a significant motor improvement even in very
disabled PD during REM sleep has been observed [8]. In
one of our patients living in a nursery home, a dramatic
improvement of locomotion during sleep as compared to
wakefulness was similarly reported by his caregiver.
Sleepwalking and Parkinson’s disease: association
with hallucinations and cognitive decline
The significantly higher frequency of visual hallucinations
in the SW group could just reflect a more advanced PD [18,
19]. The relation of VH with SW could arise, however,
from similar neurodegenerative changes in brainstem and
limbic structures [19]. Pathological changes in the amyg-
dala correlate in fact with the occurrence of VH in PD [20,
21]; amygdala is on the other hand known to be involved in
sleep-wake regulation and emotional control. Nocturnal
agitation with VH resulting in the course of cognitive
decline, as a third hypothesis, could mimic SW. Cognitive
dysfunction is indeed common in PD, including impair-
ment in executive functions and slowed information pro-
cessing (bradyphrenia) [22, 23]. Nighttime wandering
behaviors have been reported especially in male PD
patients with severe cognitive decline living in nursing
homes [24]. It is also typical for severe Alzheimer’s disease
[25]. Bliwise et al. [26] reported an even higher frequency
of disruptive nocturnal behaviors in PD than in AD. This
behavior (described as ‘‘sundowning phenomenon’’)
appears predominantly in the evening hours when patients
are still awake [27], while SW typically occurs hours after
sleep onset. Whether SW in PD is linked to cognitive
decline could unfortunately not be tested in our study.
Future studies in patients with neurodegenerative dis-
orders should assess the relationship between SW, sun-
downing, and other nighttime wandering behaviors, and
test the hypothesis that they all may belong to the clinical
spectrum of the same underlying dysfunction of arousal/
and motor control (see also Conclusions section).
Sleepwalking and Parkinson’s disease: association
with REM sleep behavior disorder
Patients with SW had higher scores in the RBDSQ. It was
considered by its original authors that RBDSQ poorly dis-
criminates patients with the most challenging differential
diagnoses of RBD such as SW or epilepsy [17]. This could in
fact explain the high RBDSQ scores in our patients. As a
matter of fact, this questionnaire has never been validated
in PD patients. The frequency of RBD in PD, as diag-
nosed by questionnaires, is different from video-poly-
somnographically diagnosed RBD (its frequency ranges
from 33–47%), demonstrating the difficulty to predict RBD
clinically [14, 28, 29]. It should be noted, however, that in a
recent Japanese study, 54% of PD patients studied were
diagnosed with RBD, based on questionnaire data [30]. If on
one hand it is difficult to discriminate SW from RBD, based
on questionnaire data, on the other hand the presence of one
disorder does not necessarily exclude the other. For exam-
ple, in our previous series of six patients with SW, four had
RBD as well [10]. We postulate that a certain number of the
PD patients suffer from both SW and RBD, a condition
called ‘‘overlap parasomnia’’.
As discussed previously [10], this raises two patho-
physiological explanations.
First, SW may represent an extreme, severe manifesta-
tion of motor dyscontrol in RBD and therefore belongs to
the spectrum of this REM parasomnia. Getting out of bed
and walking has been reported in a few series of patients
with idiopathic and symptomatic RBD and was interpreted
as a part of RBD motor activity [11, 12]. However, SW has
not been documented with video-PSG to arise from REM
sleep. In a detailed analysis of 100 consecutive patients
with PD and a history of RBD, SW was observed in only
one patient in whom RBD could not be demonstrated by
video-PSG [8]. In addition, the characteristics of behavior
in RBD and SW differ: RBD is usually described to be
associated with short, jerky, rough and repetitive move-
ments, although in 18% of the patients, not only violent
movements are described but also gestures and complex
movements, otherwise useless during sleep [31]. Further-
more, motor behaviors in our patients appear to be not only
of a longer but also a more elaborate and physiological
nature, similar to everyday activities (e.g., preparing a
meal, fishing, climbing on furniture, framing pictures, etc.;
see Results section above). Finally, although the combi-
nation of SW and RBD appears to be common in PD, not
all of our patients had questionnaire results suggesting
RBD, neither in the general section nor in the RBDSQ, thus
suggesting that RBD is not mandatory for the appearance
of de novo SW in patients with PD.
Second, the simultaneous occurrence of SW and RBD
could suggest a common underlying disturbance of motor
control during sleep in PD, with variable manifestations
according to different sleep stages. This coexistence of SW
and RBD during NREM and REM sleep, respectively, was
named ‘‘overlap parasomnia’’, by Schenck et al. [32] in 33
patients. In that series, although an underlying disorder was
found in a third of the patients, none had PD. Overlap
parasomnia was rarely documented in the course of neu-
rodegenerative diseases.
Sleepwalking and Parkinson’s disease:
other associations
Although conditions such as sleep apnea syndrome, RLS,
or periodic limb movements in sleep have been shown to
J Neurol (2011) 258:1261–1267 1265
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trigger SW [33], we did not find significant differences
regarding these symptoms.
Patients with SW also showed a trend towards a higher
ESS. EDS in PD in general is multifactorial, in this case
one possible explanation is sleep disruption due to SW,
RBD, nightmares and hallucinations. EDS could also
reflect a more advanced disease [34], in our case as
expressed by longer disease duration in patients with SW.
Two of our patients claimed that biperiden had triggered
SW episodes. Interestingly, one told that episodes ceased
with stopping this anticholinergic treatment. Although
neuro- and psychotropic medication has been described to
induce confusional arousals and SW, especially lithium,
longer acting benzodiazepines, and imidazopyridines as
zolpidem and zopiclone [35, 36], our results did not show
an association between SW and CNS-acting agents,
including antiparkinsonian treatment. There was only a
trend towards a higher consumption of tricyclics, but not
for antidepressants in general.
Conclusions
As shown above, there is considerable evidence that SW in
PD is more frequent than in the general population. The
underlying pathophysiological mechanisms remain specu-
lative. Various brainstem structures involved in locomotion,
muscle tone regulation, and arousal as well as limbic and
cortical areas are known to be affected in PD. Neurode-
generative changes at this level could affect the ‘‘ascending’’
control of state transition (leading to dissociated arousals
from NREM and REM sleep) as well as the ‘‘descending’’
control of locomotion and muscle tone. Together these
changes may lead to various sleep-associated behavioral
disturbances, including SW (and more generally nighttime
wandering behavior), RBD, and overlap parasomnia, as well
as hallucinations and changes in dream generation.
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